Hazard and risk assessment of chemical mixtures using the toxic equivalency factor approach. by Safe, S H
Hazard and RiskAssessment ofChemical
Mixtures Using theToxic Equivalency
FactorApproach
Stephen H. Safe
Department ofVeterinary Physiology and Pharmacology, Texas A&M
University, College Station, Texas
There is considerable public, regulatory, and scientific concern regarding human exposure to
endocrine-disrupting chemicals, which include compounds that directly modulate steroid hormone
receptor pathways (estrogens, antiestrogens, androgens, antiandrogens) and aryl hydrocarbon
receptor (AhR) agonists, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related
compounds. Based on quantitative structure-activity relationships for both AhR and estrogen
receptor (ER) agonists, the relative potency (RP) of individual compounds relative to a standard
(e.g., TCDD and 17f-estradiol) have been determined for several receptor-mediated responses.
Therefore, the TCDD or estrogenic equivalent (TEQ or EQ, respectively) of a mixture is defined as
TEQ=£[TI xRPi or EQ=E EiE] xRP,, where T, and Ej are concentrations of individual AhR or ER
agonists in any mixture. This approach for risk assessment of endocrine-disrupting mixtures
assumes that for each endocrine response pathway, the effects of individual compounds are
essentially additive. This paper will critically examine the utility of the TEQ/EQ approach for risk
assessment, the validity of the assumptions used for this approach, and the problems associated
with comparing low dose exposures to xeno and natural (dietary) endocrine disruptors. Environ
Health Perspect 106(Suppl 4):1051-1058 (1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-4/
1051-1058safe/abstract.html
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Introduction
The potential adverse impacts ofchemicals
are dependent on a number of factors,
including levels and duration ofexposure,
chemical potency, timing of exposure,
mechanism of action, and interactions
between chemicals in a mixture. Hazard and
risk assessment ofchemicals carried out by
regulatory agencies have focused primarily
on the toxicities ofindividual compounds,
whereas wildlife and humans are exposed to
complex mixtures ofman-made compounds
that act through multiple pathways.
Moreover, the human diet contains many
natural products and cooking-derived com-
pounds that exhibit many ofthe same toxic,
mutagenic, and carcinogenic properties of
industrial-derived contaminants (1-3). In
most cases, humans are exposed to signifi-
cantly higher levels ofnatural products than
the man-made chemical toxicants that act
through the same pathway. For example,
early development of the Ames test for
detecting bacterial mutagens generated con-
siderable scientific, regulatory, and public
concern over human exposure to the many
different industrial chemicals that exhibited
mutagenic activity in one or more of the
highly sensitive bacterial tester strains (4,5).
Subsequent studies demonstrated that some
ofthe most mutagenic compounds in the
human diet are not industrial-derived
contaminants, but natural compounds that
include a complex series ofheterocyclic
aromatic amines derived from cooking pro-
teinaceous foods (e.g., fish, beef, poultry)
(6-8). Thus, the public health concern
regarding human exposure to mutagens
must take into account intake and potency
ofboth natural and man-made chemicals
that act throughvarious pathways.
Hazard and risk assessment of human
exposures to chemicals must also take into
account scenarios where chemical interac-
tions may significantly influence toxic out-
comes. For example, despite relatively high
levels of human exposure to natural car-
cinogens in the diet, there are several other
classes of natural products (e.g., flavones,
antioxidants) that inhibit P450-mediated
metabolic activation or induce detoxifying
enzymes, and these compounds may pro-
vide protection against natural or man-
made toxins (9-11). In contrast, workplace
or environmental exposures to nontoxic
levels of organochlorine solvents such as
chloroform may lead to hepatotoxic effects
if there is concurrent exposure to ketones
because of their nonadditive (synergistic)
interactions (12,13). Thus, chemical inter-
actions are important determinants in eval-
uating the potential hazards and risks of
exposure to chemical mixtures. This manu-
script will outline the development, valida-
tion, and pitfalls associated with the toxic
equivalency factor (TEF) approach for risk
assessment ofcomplex mixtures.
Toxic Equivalency Factors:
An Approach for Hazard
and Risk Assessment
The TEF approach has been extensively
used for hazard assessment of different
classes oftoxic chemical mixtures. The over-
all toxicity or toxic equivalents (TEQs) ofa
mixture are defined by the concentration of
individual compounds (CQ) in a mixture
times their relative potencies orTEFs.
TEQ= E[Ci]X TEFi
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The assumptions implicit in utilization
ofthe TEF approach indude: the individual
compounds all act through the same bio-
logic or toxic pathway; the effects ofindivid-
ual chemicals in a mixture are essentially
additive at submaximal levels ofexposure;
the dose-response curves for different con-
geners should be parallel; and the organ-
otropic manifestations ofall congeners must
be identical over the relevant range ofdoses
(14,15). TEFi values are either derived for a
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species-specific response or are a composite
value obtained from TEFs for several
responses, and individual TEFs are usually
determined relative to the activity of a
standard or reference compound. The TEF
approach has been applied to different
structural classes of compounds, includ-
ing polynuclear aromatic hydrocarbons
(PAHs), halogenated aromatic hydrocar-
bons (HAHs), and endocrine disruptors.
The utility and problems associated with
TEFs and TEQs will be discussed.
Toxic Equivalency Factor
Approach for Polynuclear
Aromatic Hydrocarbons
Individual PAHs such as benzo[a]pyrene
(B[a]P) have been extensively investigated as
carcinogens and as ligands for the aryl
hydrocarbon receptor (AhR). The carcino-
genic activity of PAHs is dependent on the
oxidative metabolic activation ofthese com-
pounds into genotoxic metabolites, which
subsequently interact with DNA to initiate
carcinogenesis. The carcinogenic potencies
ofindividual PAHs have been determined
in different bioassays and TEF values pro-
posed for various PAHs are summarized in
Table 1 (16-19). The utility of this
approach was demonstrated in studies using
relatively simple reconstituted PAH mix-
tures in rodent carcinogenicity models
(20,21). However, Warshawsky and co-
workers (22) recently demonstrated that
there are a number ofimportant factors that
can significantly modulate the genotoxicity
ofPAH mixtures, indcluding the presence or
absence ofB[a]P, the dose, and the solvents
used in carcinogen administration. This
variability ofcarcinogenic potency suggests
that the TEF approach for PAHs may not
be appropriate for some animal models.
Studies in several laboratories have investi-
gated the biochemical, toxic, and genotoxic
activities ofmanufactured gas plant (MGP)
residues, which contain complex mixtures of
PAHs (23-27). Comparisons ofthe effects
of MGP PAHs with B[a]P or a reconsti-
tuted mixture of PAH hydrocarbons sug-
gested that the mixture induced synergistic
responses or that other factors were impor-
tant. Based on results of recent studies
(24,25,28), the high activity/genotoxicity of
the MGP-PAH mixture may be due to
unidentified alkyl PAHs. For example, a
reconstituted mixture ofthe 17 major PAHs
in an MGP sample (24) did not induce
liver tumor formation in the B6C3F1 male
juvenile mouse model at a dose of 1071
mg/kg; in contrast, the field-derived sample
induced a 45% incidence ofliver tumors at
the same dose (25,28). These results
demonstrate that applications ofTEFs for
PAHs require a more detailed knowledge of
the complete composition ofthese mixtures
and the TEFs of all active components.
Thus, the approach may be useful for
defined PAH mixtures containing only par-
ent hydrocarbons; however, for mixtures
containing alkyl PAHs, the TEF approach is
not valid because ofthe minimal data avail-
able on the identities and relative potencies
ofthese compounds.
Toxic Equivalency Factor
Approach for Halogenated
Aromatic Hydrocarbons
Polychlorinated dibenzo-p-dioxins (PCDDs),
dibenzofurans (PCDFs), polychlorinated
naphthalenes (PCNs), and polychlorinated
Table 1. Different toxic equivalency factor values proposed for individual polycyclic aromatic hydrocarbon
congeners.
Compound Thorslund et al. (18) Chu and Chen (17) U.S. EPA(19) Nisbet and LaGoy(16)
Benzo[a]pyrene 1 1 1 1
Dibenzo[a,h]anthracene 1.1 0.69 1 5
Benzo[a]anthracene 0.145 0.013 0.1 0.1
Benzo[bjfluoranthene 0.140 0.08 0.1 0.1
Benzo[k1fluoranthene 0.066 0.004 0.01 0.1
Idendo(1,2,3-c,d)pyrene 0.232 0.017 0.1 0.1
Acenaphthene ND ND 0 0.001
Acenaphthylene ND ND 0 0.001
Anthracene 0.32 ND 0 0.01
Benzo[g,h,i]perylene 0.022 ND 0 0.01
Chrysene 0.0044 0.001 0.001 0.01
Fluoranthene ND ND 0 0.001
Fluorene ND ND 0 0.001
2-Methyinaphthalene ND ND 0 0.001
Naphthalene ND ND 0 0.001
Phenanthrene ND ND 0 0.001
Pyrene 0.081 ND 0 0.001
Abbreviations: ND, not determined; U.S. EPA, U.S. Environmental Protection Agency.
biphenyls (PCBs) are HAHs that are indus-
trial compounds or industrial combustion
by-products (Figure 1). These compounds
are chemically and environmentally stable
and have been identified in almost every
component ofglobal ecosystems, induding
fish and wildlife and human serum, adipose
tissue, and milk (29,30). HAHs are also
routinely detected as residues in diverse food
products, and the diet is the major source of
human exposure to HAHs (30,32).
The mechanism of action of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) and
related HAHs has been extensively investi-
gated and the results support a pathway
that involves initial ligand (HAH) binding
to the intracellular AhR, which is widely
expressed in mammalian tissues (33). The
mechanism ofAhR-mediated CYPlAI
induction has been extensively investi-
gated; the results show that the AhR is a
ligand-induced nudear transcription factor
in which transactivation is associated with
interaction of the heterodimeric nuclear
AhR complex with dioxin-responsive ele-
ments located in the 5'-promoter region of
the Ah-responsive gene (34,35). The
mechanisms ofAhR-mediated toxicity are
PCDD
PCDF
cil cl,
PCN
PCBs
TCDD
Figure 1. Halogenated aromatic hydrocarbons.
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unknown; however, it is assumed that
many of the responses are because of
altered gene expression.
Hazard and risk assessment ofPCDDs
and PCDFs initially focused on quantita-
tion ofTCDD in various environmental
samples; however, with development of
high-resolution analytical techniques cou-
pled with studies on structure-toxicity rela-
tionships, it was apparent that the bulk of
the toxicity induced by most PCDD/PCDF
mixtures is not due to TCDD alone. Based
on the well-characterized structure-activity
relationships established for PCDDs and
PCDFs (36-39), a TEF approach has been
developed forthesecompounds:
TEQ= E[PCDF,] x TEFiand
z[PCDDj] x TEFi
where [PCDDi] and [PCDF] represent the
concentrations of the individual com-
pounds (40-46). Individual TEFs have
been assigned to all the 2,3,7,8-substituted
PCDD and PCDF congeners (Table 2)
because these are the compounds that have
Table 2. Toxic equivalency factors for the 2,3,7,8-
substituted PCDDs and PCDFs and selected polychlori-
nated biphenyl congeners.
Congener TEF
PCDDs
2,3,7,8-TCDD 1.0
1,2,3,7,8-PentaCDD 0.5
1,2,3,4,7,8-HexaCDD 0.1
1,2,3,6,7,8-HexaCDD 0.1
1,2,3,7,8,9-HexaCDD 0.1
1,2,3,4,6,7,8-HeptaCDD 0.01
OCDD 0.001
PCDFs
2,3,7,8-TCDF 0.1
2,3,4,7,8-PentaCDF 0.5
1,2,3,7,8-PentaCDF 0.1/0.05
1,2,3,4,7,8-HexaCDF 0.1
2,3,4,6,7,8-HexaCDF 0.1
1,2,3,6,7,8-HexaCDF 0.1
1,2,3,7,8,9-HexaCDF 0.1
1,2,3,4,6,7,8-HeptaCDF 0.01
1,2,3,4,7,8,9-HeptaCDF 0.01
OCDF 0.001
PCBs
3,3',4,4',5-PentaCB 0.1
3,3',4,4',5,5'-HexaCB 0.01
3,3',4,4'-TetraCB 0.0005
2,3,3',4,4'-PentaCB 0.0001
2,3,3',4,4',5-HexaCB 0.0005
2,3',4,4',5-PentaCB 0.0001
2,3,3',4,4',5'-HexaCB 0.0005
2',3,4,4',5-PentaCB 0.0001
2,3,4,4',5-PentaCB 0.0005
Data fromAhlborg etal. (45,67).
primarily been detected in environmental
samples and are among the most potent
congeners. The TEF for each 2,3,7,8-sub-
stituted congener compared to TCDD is
variable among cell types, laboratory ani-
mal species, target organs, and responses.
Research in our laboratory has extensively
investigated the immunotoxicity-derived
TEFs for several HAHs in mouse models
(47-50); TEFs for inhibition of the
plaque-forming cell response to trinitro-
phenyl-lipopolysaccharide by 2,3,4,7,8-
pentachlorodibenzofuran in C57BL/6,
DBA/2, and B6C3F1 mice varied by
approximately 7-fold, and in some assays
this congener was more potent than
TCDD. Over a broader spectrum of
responses, TEFs for individual PCDD/
PCDF congeners can vary by over 100-fold.
The broad range ofTEF values for a specific
congener compromises the use ofa single
TEF for this congener and may over- or
underestimate the calculated TEQ for a
mixture. Variable TEFs are due to many
factors including differential pharmacoki-
netics and metabolism ofHAHs in various
in vivoand in vitrobioassays.
Validation ofthe TEF approach can be
investigated by determining the in vitro or
in vivo toxicities ofreconstituted mixtures
of PCDDs and PCDFs and comparing
their observed versus calculated potencies.
Eadon and co-workers (51) utilized a
PCDF/PCDD mixture (primarily PCDFs)
resulting from a PCB fire and compared
the calculated versus observed effects for
several end points in the guinea pig,
including decreased body and thymus
weights, increased serum triglycerides,
decreased serum alanine aminotrasferase
levels, and formation of hepatocellular
cytoplasmic inclusion bodies. Their results
showed that the experimentally observed
TEQs per kilogram ranged from 2 to 21
ppm depending on end point; the calcu-
lated value using a set ofprovisional TEFs
was 14.5 ppm. These results demonstrated
a good correspondence between the
observed and calculated values. Other
reports using multiple end points in both
in vivo and in vitro models demonstrated
that for several PCDD/PCDF mixtures,
there is a reasonable correspondence
between calculated and experimentally
determined TEQs (52-60). For more
complex mixtures containing compounds
that act through multiple pathways to give
both similar and different toxic responses,
the TEF/TEQapproach may not be appro-
priate. Moreover, it should also be noted
that even for PCDDs/PCDFs, there is some
ci cl
3,3',4,4'-tetraCB
cl ci
Cl c I
c
3,3',4,4',5-pentaCB
cl cl
Cl cl
c c3 5
3,3',4,4',5,'-hexaCB
Figure 2. Coplanar (non-ortho) polychlorinated
biphenyl congeners.
evidence that TEFs do not always predict
relative congener potency in different rat
strains (61).
Several studies have also demonstrated
that the coplanar PCBs (i.e., 3,3',4,4'-
tetra-, 3,3',4,4',5-penta, and 3,3',4,4',5,5'-
hexachlorobiphenyl [CB]) (Figure 2) bind
to the AhR and induce a broad spectrum
ofAhR-mediated biochemical and toxic
responses (62,63). Tanabe and co-workers
(64,65) first utilized CYPlAI induction-
derived TEFs (66) for coplanar PCBs and
their mono-ortho-substituted analogs to
show that these compounds contributed
substantially to the TEQs ofdiverse indus-
trial/environmental extracts. Provisional
TEFs have been proposed for coplanar and
mono-ortho coplanar PCBs and these val-
ues are used routinely for determining
total TEQs (i.e., PCDDs, PCDFs, and
PCBs) in various extracts (67). The rela-
tive TEQcontributions ofdifferent classes'
of HAHs are variable; however, there are
numerous examples that demonstrate that
PCB TEQs contribute > 50% of total
TEQs. For example, a recent study on
HAHs in a human milk sample (2 weeks
after birth) in the Netherlands showed
that TEQ values for PCDDs/PCDFs and
PCBs were 30.2 and 35.5 ppt (fat weight
basis), respectively (68).
The major problems associated with the
TEF approach for HAHs is primarily asso-
ciated with nonadditive antagonistic inter-
actions between AhR agonists (PCDDs/
PCDFs and PCBs) and PCB congeners that
exhibit response and cell/species-specific
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Table 3. Examples of antagonistic interactions of halogenated aromatic hydrocarbons: inhibition of TCDD or
3,3',4,4',5-pentaCB-induced responses.
Antagonists
1,3,6,8-TetraCDF; 2,4,6,8-tetraCDF; Aroclor 1254
2,2',4,4',5',6-HexaCB
2,2',5,5'-TetraCB
Aroclors 1232, 1242, 1248, 1254, and 1260;
reconstituted PCB mixtures; 1,3,6,8-tetraCDF,
2,3,3',4,4',5-HexaCB; 2,3,3',4,5,5'-hexaCB;
2,3,3',4,5'-PentaCB; 2,3,4,4',5,6-hexaCB;
2,2',4,4',5,6'-HexaCB; 2,2',4,4',6,6'-hexaCB;
2,2',4,4',5,5'-HexaCB
Response, animal cell
AHH/EROD activities, H411E cells
EROD activity, chick embryo hepatocytes
Luciferase activity, mouse and rat cell lines
Splenic plaque-forming cell response to sheep red
blood cells ortrinitrophenyl-lipopolysaccharide,
mouse strains
2,2',4,4',5,5'-hexaCB Serum IgM units, mice
Aroclor 1254; 2,2',4,4',5,5'-hexaCB; 2,2',5,5'-tetraCB Fetal cleft palate and hydronephrosis, mice
2,2',4,4',5,5'-HexaCB Chick embryotoxicity, malformations, edema,
liver lesions
Abbreviations: AHH, aryl hydrocarbon hydroxylase; EROD, ethoxyresorufin O-deethylase. Data from multiple
studies (69-84).
antagonistic activity (69-84) (Table 3).
Research in our laboratory has clearly
demonstrated that several PCB congeners
and some commercial mixtures exhibit
AhR antagonist activity. For example,
2,2',4,4',5,5'-hexaCB (PCB 153), a major
persistent congener in environmental sam-
ples, inhibits the following TCDD or
3,3',4,4',5-pentachlorobiphenyl-induced
responses: induction of ethoxyresorufin
O-deethylase activity in chick embryo
hepatocytes; inhibition ofthe plaque-form-
ing cell response to sheep red blood cells in
mice; inhibition ofthe plaque-forming cell
response to trinitrophenyl lipopolysaccha-
ride in mice; inhibition ofserum 1gM units
in mice; induction of fetal cleft palate in
mice; induction of chick embryo malfor-
mations; induction of chick embryo
edema; induction of chick embryo liver
lesions; and induction of fetal hydro-
nephrosis in mice. These nonadditive
interactions, coupled with the unusually
broad range of TEF values observed for
some PCB congeners (e.g., 3,3',4,4'-
tetraCB), compromises the utility of the
TEF approach for hazard and risk assess-
ment of HAHs that contain PCBs.
Therefore, TEFs/TEQs for HAHs must be
used very selectively, and more research on
the utility, applications, and limitations of
this method should be conducted.
Toxic Equivalency Factor
Approach for Endocrine
Disruptors
It has been hypothesized that industrial-
derived estrogenic compounds (xeno-
estrogens) and possibly other naturally
occurring estrogens may be responsible
for a global decrease in male reproductive
capacity (e.g., sperm counts) and
increased incidence of breast cancer in
women (85,86). The validity of these
hypotheses has been questioned (1,87),
and resolution of the role of hormonally
active compounds in human disease
requires further study.
Like AhR agonists, hormonelike
compounds that act through specific cellu-
lar receptors should be good candidates for
using a TEF approach. Verdeal and Ryan
(88) previously compared human expo-
sures to man-made and naturally occurring
estrogenic compounds using a TEF/TEQ
approach and diethylstilbestrol equivalents.
The recent discovery of a second form of
the estrogen receptor (ER), ERp (89),
further complicates development of an
estrogen equivalent (EQ) approach for
estrogenic compounds. The specific
responses that are mediated via ERa or
ERN3 have not been delineated, and relative
potency factors for these responses by dif-
ferent structural classes of natural and
man-made estrogenic compounds have not
been determined. Several groups have
reported TEFs for both natural ligands for
the ER (e.g., flavonoids, lignans) and for
xenoestrogens, which are industrial-derived
chemicals and their by-products (90-93).
Although individual TEFs have been
assigned for each compound, most assay
systems indicate that with few exceptions,
both natural and xenoestrogens are > 1000
times less potent than 17p3-estradiol (E2). A
close inspection of the data obtained for
estrogenic compounds reveals that there
are many problems in development of a
TEF approach for these compounds and
some ofthese problems are similar to those
observed for HAHs and PAHs.
Pharmacokinetics, Metabolism,
and Serum Protein Binding
The in vivo activity of natural and
man-made endocrine active agents are sig-
nificantly influenced by their uptake, distri-
bution, and metabolism. For example,
many of the organochlorine xenoestrogens
exhibit low estrogenic potency based on
results of in vitro bioassays; however, these
compounds persist in the environment and
bioaccumulate. In contrast, many naturally
occurring estrogenic flavonoids in foods are
rapidly metabolized. For example, studies in
this laboratory (94) showed that narin-
genin, a flavonoid in grapefruit juice, exhib-
ited estrogenic activity in in vitro bioassays,
whereas at doses as high as 30 to 40 mg/ani-
mal naringenin, did not induce estrogen-
sensitive responses in the rat uterus. In
contrast, in female rats cotreated with E2
plus naringenin, there was significant inhibi-
tion of E2-induced uterine wet weight,
progesterone receptor levels, peroxidase
activity, and DNA synthesis. Bisphenol A
andp-octylphenol are two estrogenic pheno-
lic compounds that exhibit similar estro-
genic potency in a number of in vitro assays
(90). Vom Saal and co-workers (95)
recently reported that prenatal to early post-
natal exposure of mice to bisphenol A
resulted in increased prostate weight in
adult male offspring, whereas p-octylphenol
was inactive in this model. The increased
toxicity of bisphenol A compared to p-
octylphenol was associated with preferential
binding of the latter compound to serum
proteins and decreased uptake in target cells.
In contrast, research in this laboratory in the
immature female rat uterus indicated that
nonylphenol was significantly more potent
than bisphenol A, which exhibited weak ER
agonist and partial antiestrogenic activity.
Thus, the potencies ofboth compounds are
highly variable and response/species specific,
suggesting that a TEF approach would have
to incorporate factors that address some
measure ofresponse specificity.
Interacdons ofEndocrine-Active
Compounds
Application of a TEF approach assumes
additive responses for compounds or mix-
tures that act through the same pathway at
submaximal doses. Arnold and co-workers
(96) initially reported that binary mixtures
ofweakly estrogenic organochlorine pesti-
cides, including dieldrin, chlordane,
toxaphene, and endosulfan, exhibited >90-
fold and > 160- to 1600-fold synergistic ER
binding and induction of reporter gene
activity in a yeast-based assay, respectively,
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compared to that observed for the com-
pounds alone. This type of nonadditive
interaction would negate a TEF/EQ
approach for hazard assessment of these
mixtures. However, studies from other lab-
oratories (97,98) using the same com-
pounds have not observed synergism. The
paper on synergism was recently withdrawn
(99); however, this does not preclude the
possibility ofothersynergistic interactions.
Interacdons between
Endocrine ResponsePathways
The TEF/EQ approach is most applicable
for hazard and risk assessment ofa specific
class ofendocrine active compounds that
act through a common receptor. However,
as noted previously, there are a number of
factors that complicate this approach and
the problems are magnified with xenoen-
docrine active agents that act through
steroid hormone receptor or thyroid hor-
mone receptor-mediated pathways. For
example, assessment ofxenoestrogen expo-
sure and potency (EQs) is complicated by
tissue-specific agonist/antagonist activities,
lack of data on intake and serum levels,
and their relative contribution to total
estrogen equivalents compared to much
higher intakes ofnatural estrogenic chemi-
cals in the diet (1). In addition, many
compounds may interact with more than
one hormone receptor and modulate
multiple endocrine response pathways.
For example, 2',3',4',5'-tetrachloro-2-
biphenylol binds to the ER and exhibits
ER-agonist activities (100,101). The same
compound also binds to the androgen
receptor in a yeast-based assay but inhibits
dihydrotestosterone-induced reporter gene
activity in human Hep G2 liver cancer cells
transiently transfected with the human
androgen receptor and an androgen-
responsive construct (102). Although
2',3',4',5'-tetrachloro-4-biphenylol did
not bind the progesterone receptor, in a
progesterone-responsive yeast assay this
hydroxy-PCB inhibited progesterone
receptor-mediated transactivation (103).
These data illustrate how one endocrine-
active compound can modulate multiple
endocrine response pathways.
Another major problem for hazard
assessment ofxenoestrogens is associated
with tissue-specific cross talk between dif-
ferent receptor-mediated pathways, which
can lead to significant modulation ofestro-
gen-induced responses. It has been pointed
out that in human breast cancer cells, cross
talk between the ER- and AhR-signaling
pathway results in inhibition ofestrogen-
induced responses (1). Although this inter-
action is likely to be cell specific, it is
possible that the estrogenic activity associ-
ated with xenoestrogens in the mammary
gland will be inhibited by both xeno AhR
and natural AhR agonists in the diet.
Research in this laboratory has also focused
on cross talk between the ER and other
receptors that bind natural dietary con-
stituents. Vitamin A, retinoids, phytol, and
phytanic acid are vitamins orplant degrada-
tion products and are also important
dietary constituents that act through the
retinoic acid and retinoic acid X receptors,
and there is cross talk between these recep-
tors and the ER. For example, all trans-
retinoic acid, 9-cis-retinoic acid, and phytol
inhibit estrogen-induced responses in breast
cancer cells, and any effects ofxenoestro-
gens in these cells would be opposed by
retinoic acid and retinoic acid X receptor
ligands. The importance of this type of
counteractive cross talk in other tissues and
organs has not been determined. These are
only some examples ofcross talk between
endocrine-signaling pathways that must be
considered in an overall risk assessment of
dietary exposure to xenoestrogens and other
xenoendocrine active compounds, as well as
natural compounds in food that act
through the same signaling pathways.
Summary
Humans and wildlife are exposed in the
diet to complex mixtures of natural and
man-made chemicals. Hazard and risk
assessment ofthese mixtures is a difficult
process and the TEF approach has been
utilized for several different classes of
chemicals, including HAHs (AhR ago-
nists), PAHs (carcinogens), and xeno-
estrogens (ER agonists). This review has
pointed out both the utility and problems
associated with the TEF approach for all
three classes of chemicals. For example,
although TEFs may be useful for regulat-
ing HAH emissions and cleanup levels,
application ofthis concept for determin-
ing dietary TEQ intakes is complicated by
the unknown contributions of naturally
occurring AhR agonists, which exhibit
both AhR agonist and antagonist activities
(2). Moreover, the issue of cross talk
between multiple endocrine pathways
would further compromise the validity of
the TEF approach when applied to dietary
intakes ofdifferent classes of man-made
and natural chemicals. Based on these
uncertainties, the TEF approach should be
used for limited applications and only
aftervalidation in animal models.
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